Product Description
A free base form of BAY 43-9006 (Sorafenib) (Cat. No. 1594-25,100). Acts as an inhibitor of Raf-1 and B-Raf (IC₅₀ = 6 and 22 nM, respectively), as well as several receptor tyrosine kinases, including VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC₅₀ = 90, 15, 20, 57, and 58 nM, respectively. It poorly inhibits ERK1, MEK1, and several other kinases (IC₅₀ = >10 μM).
A free base form of BAY 43-9006 (Sorafenib) (Cat. No. 1594-25,100). Acts as an inhibitor of Raf-1 and B-Raf (IC₅₀ = 6 and 22 nM, respectively), as well as several receptor tyrosine kinases, including VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC₅₀ = 90, 15, 20, 57, and 58 nM, respectively. It poorly inhibits ERK1, MEK1, and several other kinases (IC₅₀ = >10 μM).
Biovision | 2142 | BAY 43-9006, Free base DataSheet
Alternate Name/Synonyms: Sorafenib
Appearance: Off-white solid
Formulation: N/A
CAS Number: 284461-73-0
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₁H₁₆ClF₃N₄O₃
Molecular Weight: 464.82
Cell-Permeable?: Yes
Purity: ≥99% by HPLC
Solubilities: DMSO (200 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A Raf kinase inhibitor
MDL Number: MFCD06411450
PubChem CID: 216239
SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChi:
InChi Key: MLDQJTXFUGDVEO-UHFFFAOYSA-N